A detailed history of Acadian Asset Management LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 24,394 shares of MRSN stock, worth $39,518. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,394
Previous 71,506 65.89%
Holding current value
$39,518
Previous $143,000 67.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$1.23 - $2.25 $57,947 - $106,002
-47,112 Reduced 65.89%
24,394 $46,000
Q2 2024

Aug 06, 2024

SELL
$2.0 - $4.45 $794,834 - $1.77 Million
-397,417 Reduced 84.75%
71,506 $143,000
Q1 2024

May 10, 2024

BUY
$2.16 - $5.94 $633,128 - $1.74 Million
293,115 Added 166.72%
468,923 $2.1 Million
Q4 2023

Feb 13, 2024

SELL
$1.11 - $2.34 $197,876 - $417,144
-178,267 Reduced 50.35%
175,808 $407,000
Q3 2023

Nov 13, 2023

BUY
$1.06 - $3.91 $375,319 - $1.38 Million
354,075 New
354,075 $449,000
Q3 2020

Nov 09, 2020

SELL
$16.2 - $25.7 $2.09 Million - $3.31 Million
-128,860 Closed
0 $0
Q2 2020

Aug 12, 2020

SELL
$5.24 - $23.4 $356,466 - $1.59 Million
-68,028 Reduced 34.55%
128,860 $3.02 Million
Q1 2020

May 11, 2020

BUY
$4.41 - $9.28 $296,757 - $624,469
67,292 Added 51.92%
196,888 $1.15 Million
Q4 2019

Feb 06, 2020

BUY
$1.45 - $6.73 $40,601 - $188,446
28,001 Added 27.56%
129,596 $742,000
Q3 2019

Nov 07, 2019

BUY
$1.54 - $4.2 $78,968 - $215,367
51,278 Added 101.91%
101,595 $160,000
Q2 2019

Aug 08, 2019

BUY
$3.84 - $6.4 $193,217 - $322,028
50,317 New
50,317 $204,000
Q2 2018

Jul 24, 2018

SELL
$14.2 - $22.68 $157,421 - $251,430
-11,086 Closed
0 $0
Q1 2018

Apr 12, 2018

BUY
$13.56 - $18.48 $150,326 - $204,869
11,086 New
11,086 $175,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $157M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.